Want to join the conversation?
$VRTX's supplemental New Drug Application (sNDA) for the use of KALYDECO in people ages 2 and older with one of 23 residual function mutations was accepted for review by the FDA. More than 1,500 people with CF in the U.S. have the mutations represented in the sNDA.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.